Bionano Genomics, Inc. · NASDAQ:BNGO
Bionano Genomics — Merger or Acquisition (November 2022)
10 slides from Bionano Genomics's merger presentation, Nov 29, 2022
Slide 1: Creating an End-to-End Solution for OGM & Transforming the Way the World Sees the Genome
+ Creating an End-to-End Solution for OGM & Transforming the Way the World Sees the Genome Investor Call and Webcast November 29, 2022
Slide 2: Legal Disclaimer
Legal Disclaimer This presentation contains forward-looking statements. Forward-looking statements describe future expectations, plans, results or strategies and are generally preceded by terms such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimat
Slide 3: Bionano is Acquiring Technology to Create an End-to-End Solution for OGM
Bionano is Acquiring Technology that Can Enable it to Achieve its Goal of Creating an End-to-End Solution for OGM DNA Data Data DNA Isolation + Labeling + + Processing + Analysis (2021) Every genome analysis begins at the sample …. 3
Slide 4: Purigen Biosystems Corporate Overview
Purigen Biosystems Corporate Overview • Purigen Biosystems was formed in 2012 with technology exclusively licensed from Stanford University • Core technology, isotachophoresis (ITP), was developed in the Stanford Microfluidics Laboratory led by Dr. Juan Santiago • Dr. Klint Rose, CSO and co-founder
Slide 5: Ionic Purification System
Ionic Purification System • Purigen’s Ionic Purification System – Commercially available platform for isolation of DNA and RNA – Uses isotachophoresis (ITP) for isolation and purification – Addresses complex biological samples including those with low cell counts – Purifies 8 samples in 1 hour with
Slide 6: Expected Strategic Benefits of the Transaction
Expected Strategic Benefits of the Transaction Expected to be a key step in simplifying the end-to-end workflow for OGM – potential for fast, easy & robust routine use at scale Expands Bionano’s technology portfolio for sample preparation & adds an automation platform designed for rapid, high throug
Slide 7: Integration Plan
Integration Plan • Dr. Klint Rose, co-founder and CSO, will become a Bionano fellow and lead development of ITP solutions for OGM • Existing location for Purigen in Pleasanton, CA will remain in use • Current Purigen employees are expected to join Bionano and become part of the appropriate functiona
Slide 8: Summary of Deal Terms
Summary of Deal Terms • Up to $64M in total cash consideration o $32M to be paid at closing, subject to adjustment, and up to $32M to be paid in the future based on achievement of certain milestones • Expected to close on or before December 8, 2022 8
Slide 9: Questions & Answers
Questions & Answers Contact: R. Erik Holmlin Chris Stewart CEO CFO eholmlin@bionanogenomics.com cstewart@bionanogenomics.com
Slide 10: Transforming the Way the World Sees the Genome
+ Transforming the Way the World Sees the Genome November 29, 2022 10
Bionano Genomics — Merger or Acquisition (November 2022) on 6ix